CAR-T therapy in China: 10 approved products and what they cost
China's drug regulator (NMPA) has approved 10 CAR-T cell therapies, most of them developed in China and not available in the US — including the world's first CAR-T for a solid tumor (gastric cancer), approved in June 2026.[1][2] Published prices in China range from about ¥990,000 to ¥1,290,000 per dose (about $147,982–$192,825).[3][2]
All CAR-T products approved in China
| Product | Target | Approved for | Year | Also in the US? |
|---|---|---|---|---|
| 阿基仑赛 (奕凯达) axicabtagene ciloleucel Fosun Kite | CD19 | Relapsed or refractory large B-cell lymphoma after two or more lines of therapy[4] | 2021 | Yes |
| 瑞基奥仑赛 (Carteyva / 倍诺达) relmacabtagene autoleucel JW Therapeutics | CD19 | Relapsed or refractory large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma[4] | 2021 | No — China only |
| 伊基奥仑赛 (Fucaso / 福可苏) equecabtagene autoleucel IASO Bio | BCMA | Adults with relapsed or refractory multiple myeloma[4] | 2023 | No — China only |
| 纳基奥仑赛 (源瑞达) inaticabtagene autoleucel Juventas Cell Therapy | CD19 | Relapsed or refractory large B-cell lymphoma; adult relapsed or refractory B-cell acute lymphoblastic leukemia[4] | 2023 | No — China only |
| 泽沃基奥仑赛 (赛恺泽) zevorcabtagene autoleucel CARsgen Therapeutics | BCMA | Multiple myeloma that progressed after at least three lines of therapy[4] | 2024 | No — China only |
| 西达基奥仑赛 (Carvykti) ciltacabtagene autoleucel Legend Biotech | BCMA | Adults with relapsed or refractory multiple myeloma after at least three prior lines of therapy[5][4] | 2024 | Yes |
| 雷尼基奥仑赛 (恒凯莱) Shanghai Hrain Biotechnology | CD19 | Adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy[4] | 2025 | No — China only |
| 普基奥仑赛 (普利得凯) Chongqing Precision Biotech | CD19 | Patients aged 3–21 with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia (conditional approval)[6] | 2025 | No — China only |
| 舒瑞基奥仑赛 (恺力美) satricabtagene autoleucel CARsgen Therapeutics | Claudin18.2 | Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after at least two lines of therapy — the first CAR-T approved anywhere for a solid tumor[2][4] | 2026 | No — China only |
| 泊基奥仑赛 Immunochina (IM19) | CD19 | Adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy[7][1] | 2026 | No — China only |
As of Nov 7, 2026. Chinese generic names are shown because several products have no English name yet.
Cost: China vs the US
| China, published price per dose | ¥990,000–¥1,290,000 (≈ $147,982–$192,825)[3][4][8] |
|---|---|
| 阿基仑赛 | ¥1,200,000 (≈ $179,372)[4] |
| 瑞基奥仑赛 | ¥1,290,000 (≈ $192,825)[4] |
| 舒瑞基奥仑赛 | ¥990,000 (≈ $147,982)[2][4] |
| US, Medicare average CAR-T payment | about $570,000 (July 2026)[9] |
The drug price is only part of the bill: hospital stay, cell collection, conditioning chemotherapy and monitoring are extra in both countries. In China, city "Huimin Bao" insurance and a 2025 commercial insurance drug list cover some CAR-T products[3] — but these schemes are for people insured in China. Foreign patients should expect to pay the full price unless their own international insurer agrees to cover it.
How long you need to stay
- Assessment at the hospital: records, scans, and tests for the target (for example Claudin18.2 for gastric cancer).
- Cell collection (apheresis).
- Manufacturing: current autologous CAR-T products take about 2–3 weeks to make.[4]
- Infusion and close monitoring in or near the hospital.
Plan for more than 30 days in total. Citizens of many countries can enter China visa-free for up to 30 days, but that may not cover the whole treatment. Medical treatment is not among the purposes officially listed for visa-free entry or 240-hour transit. If you are travelling mainly for planned treatment, ask a Chinese embassy or visa center which visa to apply for before you book. Check your visa options.
Where it is given
- Renji Hospital International Clinic — Started Claudin18.2 CAR-T cell collection for gastric cancer patients (July 2026)[10]
- Shanghai Jiahui International Hospital — Collected cells from the first foreign patient (from New Zealand) for Claudin18.2 CAR-T, July 2026[10]
- Shanghai Tongji Hospital — Official listing names "CAR-T for hematological malignancies" as a featured treatment[11]
CAR-T is given at certified hospital centers. Ask the international department of any hospital whether it offers the specific product you are asking about.
Related
- Claudin18.2 CAR-T for gastric cancer (satri-cel)
- Cancer drugs approved in China but not in the US
- Hospitals in Shanghai for foreigners · Beijing
Sources
Last verified: Nov 7, 2026. We re-check official pages regularly; rules and prices can change without notice. How we update
- 艺妙神州首个创新药获批上市 (Immunochina's first product approved; 9 CAR-Ts approved before it) — Sina News, published Nov 5, 2026. Checked Nov 7, 2026.
- 全球首款实体瘤CAR-T细胞治疗产品在中国获批上市 (World's first solid-tumor CAR-T approved in China) — The Paper, published Jun 22, 2026. Checked Nov 7, 2026.
- 120降至20万？国产CAR-T申报上市 (China CAR-T prices ¥999,000–¥1,290,000 per dose; payer coverage) — 21st Century Business Herald, published May 8, 2026. Checked Nov 7, 2026.
- 2026年CAR-T用药全景：9款已上市 (Overview of the 9 CAR-T products approved in China, Aug 2026) — Sohu Health (medical media summary), published Aug 13, 2026. Checked Nov 7, 2026.
- Legend Biotech's cilta-cel approved in China for multiple myeloma — Pharma Focus Asia, published Aug 27, 2024. Checked Nov 7, 2026.
- 国内首款儿童白血病CAR-T"普基奥仑赛"获批上市 (Pediatric B-ALL CAR-T approved, Nov 2025) — Pharnex Cloud, published Nov 7, 2025. Checked Nov 7, 2026.
- 国家药监局批准泊基奥仑赛注射液上市 (NMPA approves IM19 CAR-T) — Sohu (NMPA announcement reprint), published Nov 5, 2026. Checked Nov 7, 2026.
- USD/CNY exchange rate (daily) — ExchangeRate-API open data, published Nov 7, 2026. Checked Nov 6, 2026.
- CMS payment amounts for CAR-T products (Addendum B, Sept 2026); average CAR-T lump-sum ~$570,000 (Jul 2026) — American Society for Apheresis, summarizing CMS. Checked Nov 7, 2026.
- 全球首款实体瘤CAR-T细胞治疗走向临床，上海多家医院开展患者治疗 (Shanghai hospitals start treating patients, incl. first foreign patient) — Sina Finance / The Paper, published Jul 14, 2026. Checked Nov 7, 2026.
- Shanghai Tongji Hospital — Shanghai Municipal Government (source: Shanghai Municipal Health Commission). Checked Nov 6, 2026.
Planning treatment in China? Tell us what you need
Tell us what you are looking for. We use these requests to decide which hospitals, cities and prices to research next. We do not reply with quotes and we do not book appointments.